Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood
Authors:
- Jin-Tai YuJYJin-Tai Yu
- Raffaele FerrariRFRaffaele Ferrari
- 9 November 2022
- journal article
- research article
- Published by Elsevier in Biological Psychiatry
- Vol. 93 (9) , 770-779
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82071201)
- Fudan University (3030277001)
- Science and Technology Commission of Shanghai Municipality (2018SHZDZX01)
- Huashan Hospital (2022QD002)
- State Key Laboratory of Medical Neurobiology (81971032)
- Medical Research Council
- University of Washington
This publication has 39 references indexed in Scilit:
- Genomic atlas of the human plasma proteomeNature, 2018
- DrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Research, 2017
- Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular diseasePLOS Genetics, 2017
- PhenoScanner: a database of human genotype–phenotype associationsBioinformatics, 2016
- Human dehydrogenase/reductase (SDR family) member 11 is a novel type of 17β-hydroxysteroid dehydrogenaseBiochemical and Biophysical Research Communications, 2016
- Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methodsStatistics in Medicine, 2015
- The support of human genetic evidence for approved drug indicationsNature Genetics, 2015
- Frontotemporal dementia and its subtypes: a genome-wide association studyThe Lancet Neurology, 2014
- Joining forces to fight neurodegenerative diseasesThe Lancet Neurology, 2013
- HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variantsNucleic Acids Research, 2011